PRESS-RELEASE ·Filed Apr 30, 2026
Press release: earnings
Actionable Insight • Neutral
Monitor the May 7 release for clinical pipeline updates and cash runway details, which are the primary value drivers for a pre-revenue biotech. The stock has historically declined sharply around prior earnings events, so position accordingly.
Final — all horizons settled through T+60d
QNRX ▼ -33.80% at T+60d
NEUTRAL call ✗ call lost -33.80% · α vs SPY -36.90% · entry $6.48 → $4.29
T+1d
-4.17%
call -4.17% · α -4.39%
$6.21
settled 6mo ago
T+5d
-0.77%
call -0.77% · α -2.50%
$6.43
settled 6mo ago
T+20d
-23.77%
call -23.77% · α -28.73%
$4.94
settled 5mo ago
T+60d
-33.80%
call -33.80% · α -36.90%
$4.29
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Quoin Pharmaceuticals announced it will release Q1 2026 financial results and a corporate update on May 7, 2026. The filing is a routine earnings date announcement with no financial data or guidance provided.
Key Facts
- Q1 2026 results and corporate update to be released before market open on May 7, 2026
- No preliminary financial results or guidance were disclosed in this filing
- The company is a late clinical-stage specialty pharmaceutical firm focused on rare and orphan diseases
Financial Impact
No financial data provided in this filing
Risk Factors
- No revenue or earnings data disclosed — full picture only available on May 7
- Historical pattern of significant negative stock moves around prior earnings releases
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3284845 |
14 reports for QNRX
50% Hit rate best @ T+5▲ +18.63%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 6d ago | ANALYST-UPGRADE | $4.36 $4.15 | ▼ −4.82% | ▼ −4.80% | $3.90 (−10.55%) |
Sep 2, 2026 6w ago | Insider Cluster | $6.74 $7.87 | ▲ +16.77% | ▲ +15.72% | $3.90 (−42.14%) |
Aug 28, 2026 7w ago | 8-K | $6.12 $6.22 | ▲ +1.63% | ▲ +1.93% | $3.90 (−36.27%) |
Aug 28, 2026 7w ago | Press Release | $6.12 $6.22 | ▼ −1.63% | ▼ −1.93% | $3.90 (+36.27%) |
Aug 28, 2026 7w ago | Press Release | $6.12 $6.22 | ▲ +1.63% | ▲ +1.93% | $3.90 (−36.27%) |
Aug 20, 2026 8w ago | 8-K | $5.57 $5.42 | ▼ −2.69% | ▼ −2.40% | $3.90 (−29.98%) |
Aug 7, 2026 10w ago | Press Release | $4.79 $5.36 | ▲ +11.90% | ▲ +11.93% | $3.90 (−18.58%) |
Jun 23, 2026 16w ago | 8-K | $3.83 $4.20 | ▲ +9.66% | ▲ +9.52% | $3.90 (+1.83%) |
May 7, 2026 23w ago | Press Release | $6.37 $5.93 | ▼ −6.91% | ▼ −7.74% | $3.90 (−38.78%) |
May 5, 2026 23w ago | ANALYST-UPGRADE | $6.31 $6.43 | ▲ +1.90% | ▲ +0.52% | $3.90 (−38.19%) |
Showing 10 of 14
US Market Status
Market Closed — Opens in 5h 47m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access